Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy

World Journal of Surgical Oncology
Katsuhiro YoshikawaTomoharu Sugie

Abstract

We aimed to investigate the usefulness of magnetic resonance imaging (MRI) and histopathological shrinkage patterns to formulate a predictive equation for estimating residual tumor size after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients. We enrolled 34 TNBC patients who underwent MRI before and after NAC. The MRI and histopathological shrinkage patterns were analyzed and classified into five categories-types I and II (concentric shrinkage without or with surrounding lesions, respectively), type III (shrinkage with residual multinodular lesions), type IV (diffuse contrast enhancement in the entire quadrant), and non-visualization. The residual tumor sizes following MRI and histopathological examination were also compared. The most common MRI and histopathological shrinkage pattern was type I (41.2% and 38.2%, respectively), followed by non-visualization (26.5% and 32.4%, respectively); the concordance rate between MRI and histopathological shrinkage patterns was 41.2%. There was a strong correlation between MRI tumor size and pathological tumor size (r = 0.89). Based on these findings, a predictive equation for pathological tumor size was formulated as follows: pathological tumor size (mm) = 1....Continue Reading

References

Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherN V Dimitrov
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherH D Bear
Aug 11, 2001·Seminars in Oncology·E P Mamounas, B Fisher
Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GoldhirschH J Senn
Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·Keith N OgstonSteven D Heys
Feb 3, 2005·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jan 9, 2013·Journal of the National Cancer Institute·Michael L MarinovichStefano Ciatto
Dec 8, 2017·Breast Cancer Research and Treatment·José H VoldersM Petrousjka van den Tol

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
biopsy

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.